{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T16:55:14Z","timestamp":1793638514696,"version":"4.5.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2005,9,1]],"date-time":"2005-09-01T00:00:00Z","timestamp":1125532800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,12,7]],"date-time":"2015-12-07T00:00:00Z","timestamp":1449446400000},"content-version":"vor","delay-in-days":3749,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2005,9]]},"DOI":"10.1111\/j.1523-1755.2005.00511.x","type":"journal-article","created":{"date-parts":[[2005,8,11]],"date-time":"2005-08-11T13:36:20Z","timestamp":1123767380000},"page":"1190-1198","source":"Crossref","is-referenced-by-count":170,"title":["Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria"],"prefix":"10.1016","volume":"68","author":[{"given":"Kasper","family":"Rossing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrine J.","family":"Schjoedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Berit R.","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frans","family":"Boomsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Henrik","family":"Parving","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/j.1523-1755.2005.00511.x_bb0010","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.2337\/diacare.27.5.1047","article-title":"Global prevalence of diabetes\u2014Estimates for the year 2000 and projections for 2030","volume":"27","author":"Wild","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1111\/j.1523-1755.2005.00511.x_bb0015","series-title":"Brenner and Rector's the Kidney","first-page":"1777","article-title":"Diabetic nephropathy (chapter 38)","author":"Parving","year":"2004"},{"key":"10.1111\/j.1523-1755.2005.00511.x_bb0020","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1056\/NEJM198402093100605","article-title":"Microalbuminuria predicts clinical proteinuria and early mortality in maturity onset diabetes","volume":"310","author":"Mogensen","year":"1984","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1523-1755.2005.00511.x_bb0025","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s001250050140","article-title":"Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment","volume":"37","author":"Rossing","year":"1994","journal-title":"Diabetologia"},{"issue":"Suppl 45","key":"10.1111\/j.1523-1755.2005.00511.x_bb0030","first-page":"S174","article-title":"Short-term antiproteinuric response to antihypertensive treatment predicts long-term GFR decline in patients with non-diabetic renal disease","volume":"45","author":"Apperloo","year":"1994","journal-title":"Kidney Int"},{"key":"10.1111\/j.1523-1755.2005.00511.x_bb0035","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1161\/01.CIR.0000139860.33974.28","article-title":"Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy","volume":"110","author":"de Zeeuw","year":"2004","journal-title":"Circulation"},{"key":"10.1111\/j.1523-1755.2005.00511.x_bb0040","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1111\/j.1523-1755.2004.00653.x","article-title":"Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL","volume":"65","author":"de Zeeuw","year":"2004","journal-title":"Kidney Int"},{"key":"10.1111\/j.1523-1755.2005.00511.x_bb0045","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1161\/01.HYP.0000154082.72286.2a","article-title":"Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: Losartan intervention for endpoint reduction in hypertension study","volume":"45","author":"Ibsen","year":"2005","journal-title":"Hypertension"},{"key":"10.1111\/j.1523-1755.2005.00511.x_bb0050","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1161\/01.HYP.0000154083.60540.10","article-title":"Reduction in microalbuminuria: A biomeasure of therapeutic success?","volume":"45","author":"Weir","year":"2005","journal-title":"Hypertension"},{"key":"10.1111\/j.1523-1755.2005.00511.x_bb0055","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1038\/ki.1990.217","article-title":"Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules?","volume":"38","author":"Remuzzi","year":"1990","journal-title":"Kidney Int"},{"key":"10.1111\/j.1523-1755.2005.00511.x_bb0060","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1523-1755.2005.00511.x_bb0065","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1523-1755.2005.00511.x_bb0070","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1523-1755.2005.00511.x_bb0075","first-page":"585","article-title":"Diabetic nephropathy","volume":"25","author":"American Diabetes Association","year":"2002","journal-title":"Diabetes Care"},{"key":"10.1111\/j.1523-1755.2005.00511.x_bb0080","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1161\/01.HYP.31.6.1311","article-title":"Dose-related efficacy of irbesartan for hypertension\u2014An integrated analysis","volume":"31","author":"Reeves","year":"1998","journal-title":"Hypertension"},{"key":"10.1111\/j.1523-1755.2005.00511.x_bb0085","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1080\/00365517609068016","article-title":"Selection of routine method for determination of glomerular filtration rate in adult patients","volume":"36","author":"Brchner-mortensen","year":"1976","journal-title":"Scand J Clin Lab Invest"},{"key":"10.1111\/j.1523-1755.2005.00511.x_bb0090","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1161\/01.HYP.5.2.244","article-title":"Asynchronous changes in prorenin and renin secretion after captopril in patients with renal-artery stenosis","volume":"5","author":"Derkx","year":"1983","journal-title":"Hypertension"},{"key":"10.1111\/j.1523-1755.2005.00511.x_bb0095","series-title":"Mixed-Effects Models in S and S-Plus","author":"Pinhero","year":"2000"},{"key":"10.1111\/j.1523-1755.2005.00511.x_bb0100","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1093\/ndt\/18.2.293","article-title":"Time course of the antiproteinuric and antihypertensive effect of losartan in diabetic nephropathy","volume":"18","author":"Andersen","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"10.1111\/j.1523-1755.2005.00511.x_bb0105","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1093\/ndt\/16.4.771","article-title":"Time course of the antiproteinuric and renal haemodynamic responses to losartan in microalbuminuric IDDM","volume":"16","author":"Buter","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"10.1111\/j.1523-1755.2005.00511.x_bb0110","doi-asserted-by":"crossref","first-page":"150","DOI":"10.2337\/diacare.26.1.150","article-title":"Optimal dose of candesartan for renoprotection in type 2 diabetic patients with nephropathy: A double-blind randomized cross-over study","volume":"26","author":"Rossing","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1111\/j.1523-1755.2005.00511.x_bb0115","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1097\/01.ASN.0000054495.96193.BF","article-title":"Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy","volume":"14","author":"Jacobsen","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"10.1111\/j.1523-1755.2005.00511.x_bb0120","doi-asserted-by":"crossref","first-page":"2268","DOI":"10.2337\/diacare.26.8.2268","article-title":"Renoprotective effects of adding angootensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy\u2014A randomized double-blind crossover trial","volume":"26","author":"Rossing","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1111\/j.1523-1755.2005.00511.x_bb0125","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1093\/ndt\/17.8.1413","article-title":"Optimal dose of losartan for renoprotection in diabetic nephropathy","volume":"17","author":"Andersen","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"10.1111\/j.1523-1755.2005.00511.x_bb0130","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1046\/j.1523-1755.2002.00536.x","article-title":"Dual renin-angiotensin system blockade at optimal doses for proteinuria","volume":"62","author":"Laverman","year":"2002","journal-title":"Kidney Int"},{"key":"10.1111\/j.1523-1755.2005.00511.x_bb0135","series-title":"JRAAS","first-page":"196","article-title":"The effect of high-dose angiotensin II receptor blockade beyond maximal recommended doses in reducing urinary protein excretion","author":"Weinberg","year":"2001"},{"key":"10.1111\/j.1523-1755.2005.00511.x_bb0140","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1161\/01.CIR.0000024416.33113.0A","article-title":"Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus\u2014A blood pressure-independent effect","volume":"106","author":"Viberti","year":"2002","journal-title":"Circulation"},{"key":"10.1111\/j.1523-1755.2005.00511.x_bb0145","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s001250051259","article-title":"Glomerular hypertension as one cause of albuminuria in type II diabetic patients","volume":"42","author":"Imanishi","year":"1999","journal-title":"Diabetologia"},{"key":"10.1111\/j.1523-1755.2005.00511.x_bb0150","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1111\/j.1523-1755.2000.00386.x","article-title":"Glomerular permselectivity in early stages of overt diabetic nephropathy","volume":"58","author":"Andersen","year":"2000","journal-title":"Kidney Int"},{"key":"10.1111\/j.1523-1755.2005.00511.x_bb0155","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1007\/s001250100546","article-title":"Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension","volume":"44","author":"Bonnet","year":"2001","journal-title":"Diabetologia"},{"key":"10.1111\/j.1523-1755.2005.00511.x_bb0160","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/00041552-200401000-00012","article-title":"New insights into the significance of microalbuminuria","volume":"13","author":"Macisaac","year":"2004","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1111\/j.1523-1755.2005.00511.x_bb0165","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/S0272-6386(01)80115-3","article-title":"Aldosterone as a mediator of progressive renal disease: Pathogenetic and clinical implications","volume":"37","author":"Epstein","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1111\/j.1523-1755.2005.00511.x_bb0170","doi-asserted-by":"crossref","first-page":"A88","DOI":"10.1007\/s00125-004-1542-0","article-title":"Aldosterone escape during angiotensin II receptor blockade in diabetic nephropathy is associated with enhanced decline in GFR","volume":"47","author":"Schjoedt","year":"2004","journal-title":"Diabetologia"},{"key":"10.1111\/j.1523-1755.2005.00511.x_bb0175","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1056\/NEJM200109203451215","article-title":"Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease","volume":"345","author":"Chrysostomou","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1523-1755.2005.00511.x_bb0180","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1464-5491.2004.01194.x","article-title":"The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study","volume":"21","author":"Rachmani","year":"2004","journal-title":"Diabetic Med"},{"key":"10.1111\/j.1523-1755.2005.00511.x_bb0185","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1185\/030079904X3861","article-title":"The effect of irbesartan in reducing cardiovascular risk in hypertensive type 2 diabetic patients: an observational study in 16,600 patients in primary care","volume":"20","author":"Bramlage","year":"2004","journal-title":"Curr Med Res Opin"},{"key":"10.1111\/j.1523-1755.2005.00511.x_bb0190","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1056\/NEJMoa021778","article-title":"Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes","volume":"348","author":"Gaede","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1523-1755.2005.00511.x_bb0195","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0002-9149(98)00313-0","article-title":"Safety of irbesartan in the treatment of mild to moderate systemic hypertension","volume":"82","author":"Simon","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1523-1755.2005.00511.x_bb0200","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1159\/000078950","article-title":"Safety and tolerability of high-dose angiotensin receptor blocker therapy in patients with chronic kidney disease: A pilot study","volume":"24","author":"Weinberg","year":"2004","journal-title":"Am J Nephrol"},{"key":"10.1111\/j.1523-1755.2005.00511.x_bb0205","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"288","author":"The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group","year":"2002","journal-title":"JAMA"},{"key":"10.1111\/j.1523-1755.2005.00511.x_bb0210","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1161\/01.HYP.25.5.1042","article-title":"Reduction of salt intake during converting-enzyme-inhibitor treatment compared with addition of a thiazide","volume":"25","author":"Singer","year":"1995","journal-title":"Hypertension"},{"key":"10.1111\/j.1523-1755.2005.00511.x_bb0215","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1093\/ndt\/13.7.1682","article-title":"The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide","volume":"13","author":"Buter","year":"1998","journal-title":"Nephrol Dial Transplant"},{"key":"10.1111\/j.1523-1755.2005.00511.x_bb0220","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1046\/j.1365-2362.1999.00530.x","article-title":"Angiotensin II increases erythropoietin production in healthy human volunteers","volume":"29","author":"Freudenthaler","year":"1999","journal-title":"Eur J Clin Invest"},{"key":"10.1111\/j.1523-1755.2005.00511.x_bb0225","doi-asserted-by":"crossref","first-page":"3296","DOI":"10.2337\/diacare.26.12.3296","article-title":"Kidney function during and after withdrawal of longterm irbesartan treatment in patients with type 2 diabetes and microalbuminuria","volume":"26","author":"Andersen","year":"2003","journal-title":"Diabetes Care"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815509472?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253815509472?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T08:18:42Z","timestamp":1648455522000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253815509472"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,9]]}},"alternative-id":["S0085253815509472"],"URL":"https:\/\/doi.org\/10.1111\/j.1523-1755.2005.00511.x","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2005,9]]}}}